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Background. Type 2 diabetes arises when insulin resistance-induced compensatory insulin secretion exhausts. Insulin
resistance and/or b-cell dysfunction result from the interaction of environmental factors (high-caloric diet and reduced physical
activity) with a predisposing polygenic background. Very recently, genetic variations within four novel genetic loci (SLC30A8,
HHEX, EXT2, and LOC387761) were reported to be more frequent in subjects with type 2 diabetes than in healthy controls.
However, associations of these variations with insulin resistance and/or b-cell dysfunction were not assessed. Methodology/
Principal Findings. By genotyping of 921 metabolically characterized German subjects for the reported candidate single
nucleotide polymorphisms (SNPs), we show that the major alleles of the SLC30A8 SNP rs13266634 and the HHEX SNP
rs7923837 associate with reduced insulin secretion stimulated by orally or intravenously administered glucose, but not with
insulin resistance. In contrast, the other reported type 2 diabetes candidate SNPs within the EXT2 and LOC387761 loci did not
associate with insulin resistance or b-cell dysfunction, respectively. Conclusions/Significance. The HHEX and SLC30A8
genes encode for proteins that were shown to be required for organogenesis of the ventral pancreas and for insulin
maturation/storage, respectively. Therefore, the major alleles of type 2 diabetes candidate SNPs within these genetic loci
represent crucial alleles for b-cell dysfunction and, thus, might confer increased susceptibility of b-cells towards adverse
environmental factors.
Citation: Staiger H, Machicao F, Stefan N, Tschritter O, Thamer C, et al (2007) Polymorphisms within Novel Risk Loci for Type 2 Diabetes Determine b-
Cell Function. PLoS ONE 2(9): e832. doi:10.1371/journal.pone.0000832
INTRODUCTION
Type 2 diabetes mellitus (T2DM) reaches epidemic dimensions in
western industrialized nations and is caused by environmental
factors, such as high-caloric fat- and carbohydrate-enriched diets
and a sedentary lifestyle with markedly reduced physical activity.
Moreover, as one of the most recognized polygenic diseases,
T2DM is due to variations within several genetic loci that confer
increased susceptibility towards the above mentioned environ-
mental challenges [1]. Linkage studies, candidate-gene ap-
proaches, and genome-wide association studies identified single
nucleotide polymorphisms (SNPs) within currently up to ten genes
which associate with an increased T2DM risk. During the
pathogenesis of T2DM, insulin resistance of peripheral tissues
(liver, skeletal muscle, and adipose tissue) provokes compensatory
increments in insulin secretion by pancreatic b-cells. When insulin
resistance is no longer compensated and b-cells exhaust,
hyperglycemia arises [2]. Thus, most T2DM risk loci are supposed
to contribute to b-cell dysfunction. In fact, among the most
prominent T2DM risk loci up to now, only SNPs within PPARG
[3–5] contribute to altered insulin sensitivity, whereas SNPs within
KCNJ11 [6–8], CDKAL1 [9], and TCF7L2 [10–13] impair b-cell
function.
In the first very recently reported genome-wide association
study for T2DM [14], four novel T2DM risk loci were identified.
The role of the corresponding genes, i.e. SLC30A8, HHEX,
EXT2, and LOC387761, in the development of prediabetes
phenotypes was not assessed and is not established in the
literature. Therefore, it was the aim of the present study to test
the association of the recently identified candidate SNPs within or
near the genes SLC30A8, HHEX, EXT2, and LOC387761 with
insulin resistance and b-cell dysfunction in a thoroughly metabol-
ically characterized German population at an increased risk for
T2DM.
METHODS
Subjects
One thousand non-diabetic subjects were recruited from the
southern part of Germany and participated in the ongoing
Tu ¨bingen Family Study for T2DM (TU ¨F) which currently
includes ,2000 individuals. Recruitment of the subjects was
based on (i) exclusion of subjects with anti-glutamic acid decar-
boxylase antibodies, impaired glucose tolerance, and T2DM as
well as (ii) inclusion of subjects of whom DNA samples and
C-peptide measurements were available. From the 1000 subjects
selected in this way, 79 subjects were excluded due to incomplete
data sets. 71 % of the subjects had a recorded family history of
T2DM, i.e. at least one 2
nd-degree relative with T2DM. All
participants underwent the standard procedures of the protocol
including medical history and physical examination, assessment of
smoking status, alcohol consumption habits and activity, routine
blood tests, and oral glucose tolerance test (OGTT). A subgroup of
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euglycemic clamp. Another subgroup of the clamped subjects
(N=150) additionally agreed to undergo an intravenous glucose
tolerance test (IVGTT). The participants were not taking
any medication known to affect glucose tolerance or insulin
secretion. The participants gave informed written consent to the
study, and the protocol was approved by the local ethical
committee (Ethik-Kommission der Medizinischen Fakulta ¨t der
Universita ¨t Tu ¨bingen).
Genotyping of the study population
For genotyping, DNA was isolated from whole blood using
a commercial DNA isolation kit (NucleoSpin, Macherey & Nagel,
Du ¨ren, Germany). SNPs were genotyped using the TaqMan assay
(Applied Biosystems, Foster City, CA, USA). The TaqMan genotyp-
ing reaction was amplified on a GeneAmp PCR system 7000 (50uC
for 2 min, 95uC for 10 min, followed by 40 cycles of 95uC for 15 s
and 60uC for 1 min), and fluorescence was detected on an ABI Prism
sequence detector (Applied Biosystems, Foster City, CA, USA).
Body composition and body fat distribution
Body composition was measured by bioelectrical impedance as the
percentage of body fat. Body mass index (BMI) was calculated as
weight divided by the square of height (kg/m
2). Waist circumfer-
ence was measured in the upright position at the midpoint
between the lateral iliac crest and the lowest rib.
OGTT
Aftera10-hovernightfast,allsubjectsunderwent a75-gOGTTand
venous blood samples were obtained at 0, 30, 60, 90, and 120 min
for determination of plasma glucose, insulin, and C-peptide.
Hyperinsulinemic-euglycemic clamp and IVGTT
After an overnight fast and a 60-min. baseline period, 491 subjects
received a priming dose of insulin followed by an infusion
(40 mU/m
2) of short-acting human insulin for 120 min. A
variable infusion of 20 % (w/v) glucose was started to maintain
the plasma glucose concentration at 5.5 mM. Blood samples for
the measurement of plasma glucose were obtained at 5-min.
intervals throughout the clamp. Plasma insulin levels were
measured at baseline and in the steady state of the clamp. In
a subgroup of the clamped subjects (N=150), an IVGTT was
performed prior to the clamp, as described by the Botnia protocol
[15]. After baseline samples had been collected, a 0.3 g/kg body
weight glucose dose of a 20 % (w/v) glucose solution was given at
time 0. Blood samples for the measurement of plasma glucose,
insulin, and C-peptide were obtained at 2, 4, 6, 8, 10, 20, 30, 40,
50, and 60 min.
Determination of blood parameters
Plasma glucose was determined using a bedside glucose analyzer
(glucose oxidase method, Yellow Springs Instruments, Yellow
Springs, CO, USA). Plasma insulin levels were determined by
microparticle enzyme immunoassay (Abbott Laboratories, Tokyo,
Japan), and plasma C-peptide by radioimmunoassay (Byk-Sangtec,
Dietzenbach, Germany).
Calculations
The area under the curve (AUC) of plasma glucose levels during
OGTT was calculated as 0.5?(0.5?Glc0+Glc30+Glc60+Glc90+
0.5?Glc120). The AUC of plasma C-peptide levels during OGTT
was calculated analogously. Insulin secretion in the OGTT was
assessed by calculating the AUC of C-peptide divided through the
AUC of glucose (AUC C-pep/AUC glc). First-phase insulin
secretion (in nM) was estimated from plasma insulin and glucose
concentrations during OGTT using validated equations as
described formerly [16]. Homeostasis model assessment of insulin
resistance (HOMA-IR, in arbitrary units, U) was calculated as
(2?Glc0?Ins0)/45. Insulin sensitivity from OGTT (in arbitrary
units, U) was estimated as proposed by Matsuda and DeFronzo
[17]: 10,000/(Glc0?Ins0?Glcmean?Insmean)
K. Clamp-derived insulin
sensitivity (in arbitrary units, U) was calculated as glucose infusion
rate necessary to maintain euglycemia during the last 40 min.
(steady state) of the clamp (in mmol?kg
21?min
21) divided by the
steady-state insulin concentration.
Statistical analyses
Unless otherwise stated, the data are given as means6SE. Hardy-
Weinberg equilibrium was tested using x
2 test. Simple and
multivariate linear regression analyses were carried out after log-
transformation of data followed by ANOVA. In multivariate linear
regression models, the trait (index of insulin sensitivity/secretion)
was chosen as dependent variable. Two-group comparisons were
performed using Student’s t-test. Differences between time courses
were tested by MANOVA for repeated measures. A p-value,0.05
was considered statistically significant. In our cohort of 921
subjects, we were able to detect an effect size (d) of 1/5 standard
deviation (s) of a quantitative trait with a power of 100 % in the
additive as well as the dominant model. Effect sizes of 1/10 s were
still detected with 78 % power in the additive model and with 86
% power in the dominant model. The statistical software package
JMP 4.0 (SAS Institue, Cary, NC, USA) was used.
RESULTS
We genotyped 921 non-diabetic subjects (clinical characteristics
given in Table 1) for the three intronic SNPs rs3740878,
rs11037909, and rs1113132 of the EXT2 gene (chr. 11), for the
two SNPs rs1111875 and rs7923837 in the 39-flanking region of
the HHEX gene (chr. 10), for the non-synonymous SNP
rs13266634 (R325W) in the final exon of the SLC30A8 gene
(chr. 8), and for SNP rs7480010 in the 59-flanking region of the
hypothetical gene LOC387761 (chr. 11). During genotyping of the
first 80 subjects, the three EXT2 SNPs revealed complete genetic
linkage consistent with recent phase II data of the International
HapMap Project derived from Utah residents with ancestry from
Table 1. Clinical characteristics of the study population
(N=921).
......................................................................
women (N=571) men (N=350)
mean6SE range mean6SE range
Age (y) 38.660.5 15–69 39.060.7 18–69
BMI (kg/m
2) 29.760.4 16.3–68.5 28.560.4 18.7–67.2
Body fat (%) 35.060.4 9.0–63.7 23.160.4 6.8–62.0
Waist circumference (cm) 91.660.7 56–178 99.261.0 52–183
Fasting glucose (mM) 5.0760.02 3.00–7.17 5.1660.03 3.50–7.42
Glucose 120 min. OGTT
(mM)
6.4560.07 2.44–11.06 6.0960.09 2.67–11.06
Fasting insulin (pM) 66.962.3 11.0–614.0 59.262.7 11.0–362.0
Insulin 120 min. OGTT
(pM)
465617 43–3477 393624 22–4351
doi:10.1371/journal.pone.0000832.t001
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PLoS ONE | www.plosone.org 4 September 2007 | Issue 9 | e832northern and western Europe (release #21a January 2007, http://
www.hapmap.org/index.html.en, D9=1.0, r
2=1.0 for all three
SNP pairs). Therefore, among the EXT2 SNPs, rs11037909 was
arbitrarily chosen as representative and further analysed. Accord-
ing to HapMap data, both SNPs located within the HHEX locus
were not in complete linkage disequilibrium (D9=0.959,
r
2=0.698) and therefore analysed separately in the total study
population. The five remaining completely analysed SNPs were in
Hardy-Weinberg equilibrium (p.0.4, all) and displayed minor
allele frequencies (MAFs) similar to those recently reported [14]
(Tables 2 and 3). The overall genotyping success rate was 99.98 %,
and rescreening of 3.16 % of subjects gave 100 % identical results.
As presented in Tables 2 and 3, none of the SNPs significantly
correlated with anthropometric data, such as gender, age, BMI, or
body fat content. Only the minor allele of the SLC30A8 SNP
rs13266634 significantly correlated with elevated waist circumfer-
ence (p=0.0366) and showed a trend towards a correlation with
higher BMI (P=0.0507) pointing to an association with
abdominal adiposity (Table 2). Moreover, the minor allele of the
same SNP displayed a significant correlation with lower insulin
sensitivity, as measured by the hyperinsulinemic-euglycemic clamp
(p=0.0077) which however disappeared after adjustment for
gender, age, and BMI (significant determinants of insulin
sensitivity) (Table 2). None of the other SNPs was significantly
associated with indices of insulin sensitivity derived from OGTT
or hyperinsulinemic-euglycemic clamp (Tables 2 and 3). With
different OGTT-derived measures of insulin secretion, no reliable
associations of EXT2 SNP rs11037909, SLC30A8 SNP
rs13266634, and LOC387761 SNP rs7480010 were detected
(Table 2). However, the major alleles of both HHEX SNPs were
significantly correlated with reduced insulin secretion, as estimated
from all three OGTT-derived indices of insulin secretion, even
after adjustment for gender, age, BMI, and OGTT-derived insulin
sensitivity (significant determinants of insulin secretion) (Table 3).
Adjustment for fasting plasma glucose, instead of OGTT-derived
insulin sensitivity, resulted in very similar results (data not shown).
To assess the effects of the candidate SNPs specifically on glucose-
stimulated insulin secretion, we analysed data obtained from an
IVGTT in a subgroup of 150 subjects. The incremental AUC of
insulin levels of EXT2 SNP rs11037909 and LOC387761 SNP
rs7480010 were not significantly correlated with insulin secretion
prior to(p=0.9 and p=0.8,respectively, dominant model)aswell as
after adjustment for gender, age, BMI, and clamp-derived insulin
sensitivity (p=0.8 and p=0.6, respectively, dominant model). As
presented inFigure 1, the major alleles of SLC30A8 SNP rs13266634
and the HHEX SNP rs7923837 were significantly correlated with
reduced insulin secretion prior to adjustment (p=0.0029 and
p=0.0359, respectively, dominant model). After adjustment for
gender, age, BMI, and clamp-derived insulin sensitivity, the
SLC30A8 SNP rs13266634 and the HHEX SNP rs7923837
remained significantly correlated with insulin secretion (p=0.0416
and p=0.0254, respectively, dominant model). HHEX SNP
rs1111875 showed a trend towards an association with insulin
secretion that however did not withstand adjustment (unadjusted
p=0.09, adjusted p=0.16, dominant model). The pathophysiolog-
icalimportanceof theHHEXSNPrs7923837 wasfurtherstressedby
Figure 1. Association of SLC30A8 SNP rs13266634 (A) and HHEX SNPs rs1111875 (B) and rs7923837 (C) with glucose-stimulated insulin
secretion. Plasma levels of glucose (lower panels) and insulin (upper panels) during IVGTT. Dominant model: black circles – homozygous carriers of
the major allele; white circles: heterozygous and homozygous carriers of the minor allele.
doi:10.1371/journal.pone.0000832.g001
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PLoS ONE | www.plosone.org 5 September 2007 | Issue 9 | e832the significant correlation of its major allele with increased plasma
glucose levels at 120 min. of OGTT (Table 3).
DISCUSSION
In summary, we did not detect associations of the recently reported
T2DM candidate SNPs[14] with state-of-the-artmeasures of insulin
sensitivity. The significant correlation observed between SLC30A8
SNP rs13266634 and clamp-derived insulin sensitivity was not
retained after adjustment for gender, age, and BMI, and thus might
be due to this SNP’s effect on (abdominal) adiposity. Furthermore,
neither the representative EXT2 SNP rs11037909 nor the
LOC387761 SNP rs7480010 were associated with insulin secretion,
as assessed by OGTT and IVGTT. Moreover, neither EXT2 nor
LOC387761 could be confirmed as T2DM genes in four very
recentlypublishedgenome-wide association studies[9,18–20].Thus,
further studies that should include the analysis of the complete
genetic variation within these loci are needed to finally clarify these
genes’ roles in the pathogenesis of T2DM.
In contrast, we observed clear associations of SNP rs7923837
within the HHEX locus with insulin secretion indices derived from
OGTT as well as with glucose-stimulated insulin secretion during
the IVGTT. Even though our statistical data were not corrected
for multiple comparisons, this SNP’s association with measures of
insulin secretion derived from two independent methods (OGTT
and IVGTT) largely excludes the possibility of a by-chance
finding. Moreover, the association of SNP rs7923837 with plasma
glucose levels at 120 min. of OGTT indeed suggests a very
important role of the HHEX gene in the development of impaired
glucose tolerance and T2DM. This is further strengthened by the
aformentioned genome-wide association studies all of which
confirmed the importance of HHEX as a T2DM gene [9,18–
20]. As already pointed out by Sladek et al. [14], HHEX’s role in
the predispostion to T2DM could be attributed to this gene’s
function during organogenesis of the ventral pancreas [21,22].
At the moment, we cannot explain the discrepancy between the
association of SLC30A8 SNP rs13266634 with glucose-stimulated
insulin secretion during the IVGTT and the lack of association
with OGTT-derived parameters for insulin secretion. However,
this gene’s function as a zinc transporter in secretory vesicles of
pancreatic b-cells providing zinc for insulin maturation and/or
storage [23,24] renders this gene a very plausible candidate for b-
cell dysfunction. In addition, SLC30A8 was replicated as a T2DM
gene in three out of four of the recently reported genome-wide
association studies [18–20].
In conclusion, genetic variants of the HHEX and SLC30A8 loci
are associated with altered glucose-stimulated insulin secretion.
Therefore, the major alleles of candidate SNPs within these loci
represent crucial alleles for b-cell dysfunction and, thus, might
confer increased susceptibility of b-cells towards adverse environ-
mental factors.
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